Press release
Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing
About this update from Ocugen, Inc.
[{"type":"text","content":"MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology’s (ARVO) 2022 Annual Meeting in Denver on May 1 - 4, 2022. “We are excited to share information about two of the innovative treatments for blindness diseases we’ve been working on,” said Arun Upadhyay, PhD, Ocugen’s Senior Vice President of Research & Development. “Our breakthrough modifier gene therapy platform, OCU410, consisting of a RORA modifier gene, has the potential to treat patients with dry age-related macular degeneration (Dry-AMD). RORA regulates inflammatory and oxidative pathways associated with Dry-AMD and establishes homeostasis in molecular processes to control the disease pathophysiology. We believe that OCU200, our novel biologic product candidate, has the potential to offer a better therapy to millions of people with diabetic macular edema, diabetic retinopathy, and Wet-AMD, furthering our goal to provide a new option for people who are currently underserved.” Ocugen Presentations at ARVO 2022: Presentation Title: OCU410, a Potential Therapeutic for Dry-AMD, Suppresses Inflammatory Cytokine Gene Expression in Retinal Pigment Epithelial CellsAuthors: Dinesh K. Singh, Sree S. Kattala, Arun K. UpadhyayPresentation Type: Poster Session Presenter: Dinesh K. Singh, Principal Scientist, DiscoveryDate/Time: May 1, 2022, from 12:15 – 2:15 PM MDT Presentation Title: Binding Affinity: A Measure of Potency for OCU200, a Potential Therapeutic for the Treatment of Wet-AMD and DMEAuthors: Pratap C. Naha, Subechhya Neupane, Arun K. Upadhyay. Presentation Type: Oral PresentationPresenter: Pratahap C. Naha, PhD, Associate Director, Drug Delivery and Nanotechnology Date/Time: May 4, 2022, at 3:00 PM MDT About Dry Age-related Macular Degenerations (Dry AMD)Age-related Macular Degeneration (AMD) is characterized by thickening and loss of normal architecture within Bruch’s membrane, lipofuscin accumulation in the retinal pigment epithelium (“R...